- Home
- ACRS vs WSBF Comparison
ACRS vs WSBF Comparison
Compare ACRS & WSBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | WSBF |
|---|---|---|
| Founded | 2012 | 1921 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 336.7M |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ACRS | WSBF |
|---|---|---|
| Price | $4.85 | $18.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 55.1K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.79% |
| EPS Growth | ★ 69.01 | 46.53 |
| EPS | N/A | ★ 0.34 |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | $55.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $12.49 |
| 52 Week High | $4.94 | $18.88 |
Technical Indicators
Market Signals| Indicator | ACRS | WSBF |
|---|---|---|
| Relative Strength Index (RSI) | 64.65 | 48.96 |
| Support Level | $2.67 | $17.66 |
| Resistance Level | $4.89 | $18.62 |
| Average True Range (ATR) | 0.27 | 0.45 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 72.12 | 48.97 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The majority of its revenue comes from the Community Banking segment.